Scilex Holding Co
NASDAQ:SCLX
Scilex Holding Co
Other Items
Scilex Holding Co
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Items
-$18.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Items
-$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
-14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Items
$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Items
-$9.6B
|
CAGR 3-Years
-156%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Items
-$123m
|
CAGR 3-Years
46%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Scilex Holding Co
Glance View
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
